Deutsche Bank Raises Quest Diagnostics Target to $205, Maintains 'Hold' Rating

Deutsche Bank has adjusted its price target for Quest Diagnostics (DGX) upwards to $205 from $178. The bank, however, maintained its 'Hold' rating on the stock. This revision follows Quest Diagnostics' robust performance in Q4 2025 and optimistic guidance for 2026. The company recently reported strong earnings, indicating a positive outlook for its operations. Furthermore, Quest Diagnostics announced an increase in its quarterly cash dividend and a significant $1 billion boost to its share repurchase authorization, signaling confidence in its financial health.